

Psychopharmacologic Drugs Advisory Committee

March 23, 2006

*New Drug Application (NDA) 20-717/S-019, trade name Provigil® Tablets, Cephalon, Inc.,
proposed indication is for treatment of attention-deficit/ hyperactivity disorder (ADHD).*

ERRATA to the Transcript

On page 47, line 1: “the 0.7 would still be statistically significant” should read “the 0.07 would still be statistically significant”

On page 51, line 7: “that is with 1.5 million” should read “that is with 1,050,000”